Investors are attracted to unprofitable companies like Pieris Pharmaceuticals due to potential success. However, Pieris' high cash burn rate and short cash runway suggest it may need to raise more funds, posing a risk for shareholders. Monitoring financial health and growth metrics is crucial for investors.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing